Teladoc price target lowered to $10 from $15 at Wells Fargo

Wells Fargo analyst Stephen Baxter lowered the firm’s price target on Teladoc to $10 from $15 and keeps an Equal Weight rating on the shares. Although Teladoc’s Integrated Care has solid visibility with positive momentum, the firm doesn’t see a scenario where it outperforms enough to offset the anticipated drag from BetterHelp.